Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the
treatment of BPH (benign prostatic hyperplasia) as compared to placebo.